Advertisement

Pfizer begins testing possible COVID-19 vaccine on humans in U.S.

By
Don Jacobson
The companies said Tuesday they're preparing a large-scale rollout that will produce millions of vaccine doses this year and hundreds of millions next year. File Photo by Shutterstock/UPI
The companies said Tuesday they're preparing a large-scale rollout that will produce millions of vaccine doses this year and hundreds of millions next year. File Photo by Shutterstock/UPI

May 5 (UPI) -- U.S. pharmaceutical conglomerate Pfizer and German partner BioNTech announced Tuesday they have begun administering a potential COVID-19 vaccine to human test subjects in the United States.

The companies said they administered the experimental "BNT162" vaccine in the first U.S. patients at various sites, including New York University, the University of Maryland and Cincinnati Children's Hospital. Eventually, more than 300 U.S. participants will receive the vaccine as part of the study.

Advertisement

The initial trial is designed to determine the safety, immunogenicity and optimal dose level of four versions of Pfizer's vaccine candidate, which uses "messenger DNA" to spur the body to produce antibodies that fight the coronavirus.

The companies said they have been moving quickly in the process. They first began human trials in Germany last week.

RELATED European nations ease COVID-19 restrictions

"The short, less than four-month time frame in which we've been able to move from pre-clinical studies to human testing is extraordinary and further demonstrates our commitment," Pfizer CEO Albert Bourla said.

The companies said they're preparing a large-scale rollout that will produce millions of vaccine doses this year and hundreds of millions next year.

Pfizer's vaccine candidate is one of eight that are now in the clinical trial stage as drugmakers search for immunity against the virus that's so far killed 250,000 worldwide.

Advertisement
RELATED Original epicenters' coronavirus tolls plunge; world deaths near 250,000

A phase-one safety study of Moderna's "mRNA-1273" vaccine candidate began in March in association with the National Institutes of Health. It could advance to the second stage between now and July and the final phase possibly in the fall.

Other vaccine candidates presently in human trials include include four in China and one each at Oxford University in Britain and pharmaceutical firm Inovio.

RELATED Analysis suggests states need to plan for second wave of COVID-19

U.S. copes with COVID-19 pandemic

Bass Pro Shops marketing manager David Smith (R) carries a box of donated face masks into Mercy Health in Chesterfield, Mo., on May 13. The company is donating 1 million FDA-approved ASTM Level 1 Procedure Face Masks to healthcare workers and first responders working on the front lines of the pandemic. Photo by Bill Greenblatt/UPI | License Photo

Latest Headlines